Mycobacterium leprae transmission characteristics during the declining stages of leprosy incidence: A systematic review.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
01
12
2020
accepted:
03
05
2021
revised:
08
06
2021
pubmed:
27
5
2021
medline:
14
9
2021
entrez:
26
5
2021
Statut:
epublish
Résumé
Leprosy is an infectious disease caused by Mycobacterium leprae. As incidence begins to decline, the characteristics of new cases shifts away from those observed in highly endemic areas, revealing potentially important insights into possible ongoing sources of transmission. We aimed to investigate whether transmission is driven mainly by undiagnosed and untreated new leprosy cases in the community, or by incompletely treated or relapsing cases. A literature search of major electronic databases was conducted in January, 2020 with 134 articles retained out of a total 4318 records identified (PROSPERO ID: CRD42020178923). We presented quantitative data from leprosy case records with supporting evidence describing the decline in incidence across several contexts. BCG vaccination, active case finding, adherence to multidrug therapy and continued surveillance following treatment were the main strategies shared by countries who achieved a substantial reduction in incidence. From 3950 leprosy case records collected across 22 low endemic countries, 48.3% were suspected to be imported, originating from transmission outside of the country. Most cases were multibacillary (64.4%) and regularly confirmed through skin biopsy, with 122 cases of suspected relapse from previous leprosy treatment. Family history was reported in 18.7% of cases, while other suspected sources included travel to high endemic areas and direct contact with armadillos. None of the countries included in the analysis reported a distinct increase in leprosy incidence in recent years. Together with socioeconomic improvement over time, several successful leprosy control programmes have been implemented in recent decades that led to a substantial decline in incidence. Most cases described in these contexts were multibacillary and numerous cases of suspected relapse were reported. Despite these observations, there was no indication that these cases led to a rise in new secondary cases, suggesting that they do not represent a large ongoing source of human-to-human transmission.
Sections du résumé
BACKGROUND
Leprosy is an infectious disease caused by Mycobacterium leprae. As incidence begins to decline, the characteristics of new cases shifts away from those observed in highly endemic areas, revealing potentially important insights into possible ongoing sources of transmission. We aimed to investigate whether transmission is driven mainly by undiagnosed and untreated new leprosy cases in the community, or by incompletely treated or relapsing cases.
METHODOLOGY/PRINCIPAL FINDINGS
A literature search of major electronic databases was conducted in January, 2020 with 134 articles retained out of a total 4318 records identified (PROSPERO ID: CRD42020178923). We presented quantitative data from leprosy case records with supporting evidence describing the decline in incidence across several contexts. BCG vaccination, active case finding, adherence to multidrug therapy and continued surveillance following treatment were the main strategies shared by countries who achieved a substantial reduction in incidence. From 3950 leprosy case records collected across 22 low endemic countries, 48.3% were suspected to be imported, originating from transmission outside of the country. Most cases were multibacillary (64.4%) and regularly confirmed through skin biopsy, with 122 cases of suspected relapse from previous leprosy treatment. Family history was reported in 18.7% of cases, while other suspected sources included travel to high endemic areas and direct contact with armadillos. None of the countries included in the analysis reported a distinct increase in leprosy incidence in recent years.
CONCLUSIONS/SIGNIFICANCE
Together with socioeconomic improvement over time, several successful leprosy control programmes have been implemented in recent decades that led to a substantial decline in incidence. Most cases described in these contexts were multibacillary and numerous cases of suspected relapse were reported. Despite these observations, there was no indication that these cases led to a rise in new secondary cases, suggesting that they do not represent a large ongoing source of human-to-human transmission.
Identifiants
pubmed: 34038422
doi: 10.1371/journal.pntd.0009436
pii: PNTD-D-20-02098
pmc: PMC8186771
doi:
Substances chimiques
BCG Vaccine
0
Leprostatic Agents
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009436Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Rheumatology (Oxford). 2010 Apr;49(4):826-8
pubmed: 20026561
Am J Trop Med Hyg. 2015 Nov;93(5):1082-6
pubmed: 26304919
PLoS Negl Trop Dis. 2020 Apr 27;14(4):e0008276
pubmed: 32339201
Acta Biomed. 2019 Sep 13;90(9-S):7-14
pubmed: 31517884
Am J Trop Med Hyg. 2016 Sep 7;95(3):522-7
pubmed: 27402522
Emerg Infect Dis. 2018 Jan;24(1):165-166
pubmed: 29260666
Dermatol Res Pract. 2015;2015:253154
pubmed: 26508912
PLoS Negl Trop Dis. 2018 Jun 28;12(6):e0006532
pubmed: 29953440
PLoS Negl Trop Dis. 2011 Mar 15;5(3):e1013
pubmed: 21423643
Nihon Rai Gakkai Zasshi. 1995 Nov;64(3):214-9
pubmed: 8582880
J Infect Dis. 2005 Nov 1;192(9):1673-4; author reply 1674-5
pubmed: 16206087
Trans R Soc Trop Med Hyg. 1993 Nov-Dec;87(6):675
pubmed: 8296373
Travel Med Infect Dis. 2016 Jul-Aug;14(4):331-49
pubmed: 27393660
J Clin Rheumatol. 2011 Dec;17(8):432-5
pubmed: 22089994
JAAD Case Rep. 2016 May 12;2(3):189-92
pubmed: 27222885
Lepr Rev. 1980 Mar;51 Suppl 1:i-xi, 1-130
pubmed: 7432082
N Engl J Med. 2011 Oct 20;365(16):1549-51
pubmed: 22010934
East Mediterr Health J. 2000 Sep-Nov;6(5-6):1098-102
pubmed: 12197333
Int J Lepr Other Mycobact Dis. 2000 Mar;68(1):57-62
pubmed: 10834070
Am J Trop Med Hyg. 2013 Feb;88(2):211
pubmed: 23390219
Open Forum Infect Dis. 2018 Jun 05;5(7):ofy133
pubmed: 30046638
Sci Rep. 2019 Feb 28;9(1):3165
pubmed: 30816338
J Immigr Minor Health. 2016 Apr;18(2):490-3
pubmed: 26018958
Emerg Infect Dis. 2013 Jan;19(1):179-81
pubmed: 23260417
BMC Int Health Hum Rights. 2005 Mar 16;5(1):3
pubmed: 15771781
Lepr Rev. 2008 Dec;79(4):410-5
pubmed: 19274987
Am J Dermatopathol. 2012 Dec;34(8):e114-8
pubmed: 23169418
Lepr Rev. 1990 Dec;61(4):379-85
pubmed: 2280660
PLoS Negl Trop Dis. 2018 Dec 20;12(12):e0006910
pubmed: 30571740
Australas Med J. 2013 Apr 30;6(4):175-7
pubmed: 23671461
Lepr Rev. 2009 Dec;80(4):432-40
pubmed: 20306642
Clin Infect Dis. 2006 Jul 15;43(2):e19-22
pubmed: 16779736
Eur J Dermatol. 2018 Dec 1;28(6):843-844
pubmed: 30563805
J Am Acad Dermatol. 2006 Oct;55(4):714-6
pubmed: 17010758
Int J Mycobacteriol. 2018 Apr-Jun;7(2):173-177
pubmed: 29900896
Am J Dermatopathol. 2010 Jun;32(4):417-9
pubmed: 20216198
Australas J Dermatol. 2018 Feb;59(1):58-59
pubmed: 28660623
N Z Med J. 2015 May 15;128(1414):9-14
pubmed: 26117385
PLoS Negl Trop Dis. 2020 Feb 20;14(2):e0007891
pubmed: 32078623
Int J Dermatol. 2004 Dec;43(12):906-10
pubmed: 15569014
Am J Trop Med Hyg. 2008 Jun;78(6):962-7
pubmed: 18541777
J Am Acad Dermatol. 1983 Dec;9(6):899-903
pubmed: 6643788
Int J Lepr Other Mycobact Dis. 2003 Sep;71(3):240-3
pubmed: 14608820
JAMA. 2000 Feb 23;283(8):1004-5
pubmed: 10697058
J Am Acad Dermatol. 2011 Jan;64(1):64-70
pubmed: 20619489
Ann Intern Med. 2004 Aug 3;141(3):W51
pubmed: 15289237
J Formos Med Assoc. 2014 Sep;113(9):579-80
pubmed: 23583121
Cutis. 2017 Nov;100(5):327-329
pubmed: 29232423
Front Microbiol. 2020 Jun 16;11:1220
pubmed: 32612587
Aust N Z J Public Health. 1998 Oct;22(6):709-13
pubmed: 9848969
Emerg Infect Dis. 2015 Dec;21(12):2127-34
pubmed: 26583204
Emerg Infect Dis. 2013 Oct;19(10):1693-4
pubmed: 24050493
Lancet Infect Dis. 2014 Feb;14(2):96-8
pubmed: 24457165
BMJ Case Rep. 2019 Jun 29;12(6):
pubmed: 31256049
Lepr Rev. 2015 Dec;86(4):316-27
pubmed: 26964427
Can J Public Health. 1952 Jun;43(6):252-8
pubmed: 14935935
Lepr Rev. 2015 Jun;86(2):142-55
pubmed: 26502685
Int J Urol. 2003 Mar;10(3):177-9
pubmed: 12622716
Arch Dermatol. 1997 May;133(5):623-7
pubmed: 9158416
Case Rep Infect Dis. 2018 Aug 14;2018:6125215
pubmed: 30186647
Am J Clin Pathol. 2008 Dec;130(6):856-64
pubmed: 19019760
Nihon Hansenbyo Gakkai Zasshi. 2010 Feb;79(1):3-10
pubmed: 20169978
Lepr Rev. 1990 Mar;61(1):32-49
pubmed: 2319900
Int J Lepr Other Mycobact Dis. 2003 Jun;71(2):95-100
pubmed: 12914131
J Dermatol. 1993 Apr;20(4):226-30
pubmed: 8315112
PLoS Negl Trop Dis. 2020 Sep 16;14(9):e0008611
pubmed: 32936805
Arch Dermatol. 2011 May;147(5):624-6
pubmed: 21576589
J Pak Med Assoc. 2011 Jun;61(6):558-61
pubmed: 22204210
Travel Med Infect Dis. 2019 Sep - Oct;31:101402
pubmed: 30953714
Int J Lepr Other Mycobact Dis. 1985 Mar;53(1):79-85
pubmed: 3998564
Ned Tijdschr Geneeskd. 1994 Sep 24;138(39):1960-3
pubmed: 7935946
Arch Intern Med. 1988 Sep;148(9):1987-92
pubmed: 3046539
Arch Dermatol. 2012 Sep;148(9):1096-7
pubmed: 22986882
South Med J. 1996 Jul;89(7):647-52
pubmed: 8685748
Southeast Asian J Trop Med Public Health. 1988 Sep;19(3):515-7
pubmed: 3217829
Lepr Rev. 1990 Dec;61(4):353-65
pubmed: 2280657
Travel Med Infect Dis. 2014 Nov-Dec;12(6 Pt B):771-7
pubmed: 25458075
PLoS Negl Trop Dis. 2015 Apr 23;9(4):e0003658
pubmed: 25905706
IDCases. 2019 May 09;17:e00557
pubmed: 31193361
Am J Trop Med Hyg. 2014 Aug;91(2):216
pubmed: 25100789
Br J Dermatol. 1997 Dec;137(6):1006-10
pubmed: 9470925
Med J Aust. 2011 Aug 1;195(3):150-2
pubmed: 21806536
Eur Neurol. 2004;52(4):256-8
pubmed: 15583462
Science. 2016 Nov 11;354(6313):744-747
pubmed: 27846605
Intern Med. 2011;50(19):2223-6
pubmed: 21963745
Infection. 2019 Dec;47(6):1065-1069
pubmed: 31456174
South Med J. 2008 Jun;101(6):635-8
pubmed: 18475242
South Med J. 2011 Oct;104(10):689-94
pubmed: 21941157
PLoS Negl Trop Dis. 2020 Aug 14;14(8):e0008563
pubmed: 32797081
Int J Lepr Other Mycobact Dis. 2002 Jun;70(2):121-4
pubmed: 12211897
J Infect Dis. 2006 Feb 1;193(3):346-53
pubmed: 16388481
Lancet. 2006 Apr 29;367(9520):1458
pubmed: 16650656
J R Coll Physicians Edinb. 2015 Mar;45(1):38-42
pubmed: 25874829
Australas J Dermatol. 2009 Feb;50(1):36-40
pubmed: 19178490
Emerg Med J. 2006 Sep;23(9):699-700
pubmed: 16921083
Eur J Epidemiol. 1990 Dec;6(4):404-6
pubmed: 2091941
Lancet. 1991 Sep 21;338(8769):739-43
pubmed: 1679878
Chemotherapy. 2001 Sep-Oct;47(5):309-31
pubmed: 11561134
Southeast Asian J Trop Med Public Health. 1993 Mar;24(1):3-10
pubmed: 8362302
Emerg Infect Dis. 2011 Jul;17(7):1202-8
pubmed: 21762573
J Dermatol. 2008 Jun;35(6):354-61
pubmed: 18578713
Am J Med Sci. 2013 Jan;345(1):65-9
pubmed: 23111393
J Cutan Med Surg. 2010 Mar-Apr;14(2):95-9
pubmed: 20338126
South Med J. 2011 Jan;104(1):61-3
pubmed: 21119554
PLoS Negl Trop Dis. 2017 Nov 20;11(11):e0006028
pubmed: 29155821
Med J Aust. 1999 Jan 18;170(2):72-3
pubmed: 10026687
Actas Dermosifiliogr. 2013 Dec;104(10):915-9
pubmed: 23177396
Nihon Hansenbyo Gakkai Zasshi. 2012 Apr;81(1-2):135-43
pubmed: 22586947
J Neurol. 2015 Sep;262(9):2179-81
pubmed: 26233690
J Am Acad Dermatol. 2011 Mar;64(3):593-6
pubmed: 20494478
Am J Trop Med Hyg. 2017 Dec;97(6):1726-1730
pubmed: 29141716
Skinmed. 2017 Oct 01;15(5):391-393
pubmed: 29139372
Clin Infect Dis. 2008 Mar 15;46(6):899-901
pubmed: 18269333
CMAJ. 2004 Jan 6;170(1):55-9
pubmed: 14707220
Int J Dermatol. 2006 Nov;45(11):1321-5
pubmed: 17076715
Int J Epidemiol. 2002 Oct;31(5):991-1000
pubmed: 12435774
J Clin Microbiol. 2014 Oct;52(10):3811-2
pubmed: 25056325
PLoS Med. 2011 Mar;8(3):e1001012
pubmed: 21445325
Int J Lepr Other Mycobact Dis. 1998 Jun;66(2):125-30
pubmed: 9728444
BMJ Open. 2016 May 03;6(5):e010608
pubmed: 27142858
Lepr Rev. 2007 Mar;78(1):65-9
pubmed: 17518098
BMJ. 1991 Jun 1;302(6788):1324-6
pubmed: 2059690
Travel Med Infect Dis. 2017 Sep;19:66-67
pubmed: 28709957
Int J Lepr Other Mycobact Dis. 1995 Jun;63(2):213-21
pubmed: 7602216
PLoS Negl Trop Dis. 2016 Mar 03;10(3):e0004321
pubmed: 26939132
South Med J. 2004 Dec;97(12):1252-6
pubmed: 15646765
Joint Bone Spine. 2012 Mar;79(2):203-4
pubmed: 21944977
Lepr Rev. 2004 Mar;75(1):19-33
pubmed: 15072123
Int J Lepr Other Mycobact Dis. 2005 Jun;73(2):127-8
pubmed: 16830656
Transbound Emerg Dis. 2020 Mar;67(2):1032-1034
pubmed: 31733134
Emerg Infect Dis. 2007 Sep;13(9):1438-40
pubmed: 18252138
QJM. 2017 Nov 1;110(11):759
pubmed: 29025146